![](https://investorshub.advfn.com/uicon/182506.png?cb=1466612923)
Sunday, June 30, 2013 4:58:10 PM
6/30/2013 1:28 PM ET
Onyx Pharmaceuticals Inc. (ONXX: Quote) Sunday confirmed it received and rejected an unsolicited proposal from Amgen Inc. to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash.
The Board of Directors of Onyx had evaluated the proposal made by Amgen concluded that the price proposed by Amgen significantly undervalued Onyx and its prospects, and was not in the best interest of Onyx or its shareholders.
Onyx communicated this determination to Amgen on Friday, June 28, 2013.
Based upon expressions of interest received from other third parties and the recent proposal from Amgen, the Onyx Board has authorized its financial advisor to contact potential acquirers who may have an interest in the Company in a transaction that is in the best interest of Onyx shareholders.
Click here to receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
_____________________________________________________________
http://www.rttnews.com/2143674/onyx-pharma-rejects-unsolicited-acquisition-proposal-from-amgen.aspx
ONXX
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM